Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19

Overview of attention for article published in Proceedings of the National Academy of Sciences of the United States of America, March 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 315 X posts from 280 X users, with an upper bound of 2,955,674 followers.

RT @weinerlabhms: Published in PNAS that nasal anti-CD3 mAb (foralumab) decreases NKG7 and increases TGFB1 & GIMP7 in T cells in COVID, MS…

RT @weinerlabhms: Published in PNAS that nasal anti-CD3 mAb (foralumab) decreases NKG7 and increases TGFB1 & GIMP7 in T cells in COVID, MS…

RT @RWittenbrink: Und hier der Link zur Studie. „Die nasale Verabreichung von Anti-CD3-MAb (Foralumab) senkt die NKG7-Expression und erhö…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 311 additional X posts.